AiPD: Autoinhibited Protein Database

Q15120

Gene name	PDK3 (PDHK3)
Protein name	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial
Names	Pyruvate dehydrogenase kinase isoform 3
Species	Homo sapiens (Human)
KEGG Pathway	hsa:5165
EC number	2.7.11.2: Protein-serine/threonine kinases
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

340-406 (Predicted disordered autoinhibitory region) PR

Target domain
Relief mechanism
Assay	cis-regPred

AID

340-406 (Predicted disordered autoinhibitory region)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell Systems, 2, 89-100

Autoinhibited structure

Activated structure

6 structures for Q15120

Entry ID	Method	Resolution	Chain	Position	Source
1Y8N	X-ray	260 A	A	9-406	PDB
1Y8O	X-ray	248 A	A	9-406	PDB
1Y8P	X-ray	263 A	A	9-406	PDB
2PNR	X-ray	250 A	A/B/E/F	9-406	PDB
2Q8I	X-ray	260 A	A	9-406	PDB
AF-Q15120-F1	Predicted				AlphaFoldDB

146 variants for Q15120

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
rs1940054079 RCV001208350	5	R>W	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinVar dbSNP
RCV000543425 CA10372221 CA10372220 rs371137355	17	E>D	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen 1000Genomes ExAC TOPMed gnomAD ClinVar dbSNP
RCV001206745 CA10372232 rs757407648	50	R>Q	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar ExAC dbSNP gnomAD
RCV000694093 CA412604148 rs1569221445	54	P>S	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar Ensembl dbSNP
RCV000756466 rs375475050 RCV002533789 CA10372264	102	P>S	Variant assessed as Somatic; 0.0 impact. Charcot-Marie-Tooth disease X-linked dominant 6 [NCI-TCGA, ClinVar]	Yes	ClinGen ClinVar ESP ExAC NCI-TCGA TOPMed dbSNP gnomAD
RCV000864913 VAR_070081 RCV001173738 CA10372280 rs146331370	114	K>T	Charcot-Marie-Tooth disease X-linked dominant 6 Charcot-Marie-Tooth disease [ClinVar]	Yes	ClinGen ClinVar UniProt ESP ExAC TOPMed dbSNP gnomAD
RCV000432171 CA10372281 RCV001173742 rs138321172 RCV001081421 RCV000513112 RCV002521596	126	M>V	Charcot-Marie-Tooth disease Charcot-Marie-Tooth disease X-linked dominant 6 Inborn genetic diseases [ClinVar]	Yes	ClinGen ClinVar 1000Genomes ESP ExAC TOPMed dbSNP gnomAD
CA327704771 rs898354567 RCV001214596 RCV001508955	141	P>L	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar TOPMed dbSNP gnomAD
rs1602114620 RCV001173740 CA412605448 RCV001751304	156	T>I	Charcot-Marie-Tooth disease [ClinVar]	Yes	ClinGen ClinVar Ensembl dbSNP
VAR_070082 CA144620 RCV000054495 rs397515323 COSM3708569 RCV002513712	158	R>H	liver Charcot-Marie-Tooth disease X-linked dominant 6 Variant assessed as Somatic; impact. Inborn genetic diseases CMTX6; gain of function; results in a 5-fold increase in kinase activity, decreased sensitivity to pyruvate inhibition, reduced affinity for nucleotides and increased affinity for pyruvate dehydrogenase complex component E2 (PDC-E2), leading to PDC hyperphosphorylation and increased inactivation [Cosmic, ClinVar, NCI-TCGA, UniProt]	Yes	ClinGen cosmic curated ClinVar UniProt Ensembl NCI-TCGA dbSNP
RCV000999356 rs867468579 CA412605485 RCV001211863	162	R>H	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar Ensembl dbSNP
RCV000555849 rs1165981822 CA412605673	188	D>N	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar TOPMed dbSNP gnomAD
CA10372304 COSM78288 rs764909872 RCV001337511	193	V>M	ovary Charcot-Marie-Tooth disease X-linked dominant 6 [Cosmic, ClinVar]	Yes	ClinGen cosmic curated ClinVar ExAC dbSNP gnomAD
rs1569225940 RCV000686477	199	D>missing	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinVar dbSNP
rs1555949588 RCV000651316 CA412602235	203	T>R	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar Ensembl dbSNP
RCV001202537 rs1051776582 CA327706384	231	P>R	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar dbSNP gnomAD
CA412602726 RCV000814200 rs1569227273	271	K>E	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar Ensembl dbSNP
RCV001219332 rs1922567942	314	E>*	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinVar dbSNP
rs1569228203 CA412603604 RCV001855875 RCV000756467	360	A>V	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar Ensembl dbSNP
rs1569228214 RCV000699821	363	S>missing	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinVar dbSNP
RCV001233818 rs1922715042	366	F>C	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinVar dbSNP
RCV001227739 rs1922715462	369	L>P	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinVar dbSNP
RCV001173739 rs1922715641	372	F>*	Charcot-Marie-Tooth disease [ClinVar]	Yes	ClinVar dbSNP
rs781166988 RCV000688385 CA10372401	376	A>T	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar 1000Genomes ExAC dbSNP gnomAD
CA412603765 RCV001322360 rs1442646183 COSM1119515	383	T>M	Variant assessed as Somatic; 0.0 impact. Charcot-Marie-Tooth disease X-linked dominant 6 endometrium [NCI-TCGA, ClinVar, Cosmic]	Yes	ClinGen cosmic curated ClinVar NCI-TCGA dbSNP gnomAD
rs762702094 CA10372408 RCV001349403	402	Y>C	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar ExAC dbSNP gnomAD
CA10372409 RCV001339282 rs375862167	404	A>V	Charcot-Marie-Tooth disease X-linked dominant 6 [ClinVar]	Yes	ClinGen ClinVar ESP ExAC TOPMed dbSNP gnomAD
rs758776608 CA10372217	2	R>P		No	ClinGen ExAC gnomAD
rs758776608 CA412603096	2	R>Q		No	ClinGen ExAC gnomAD
CA10372218 rs780490485	4	F>V		No	ClinGen ExAC gnomAD
CA412603112 rs1215980952	5	R>Q		No	ClinGen TOPMed
CA412603140 rs1486473032	9	K>N		No	ClinGen gnomAD
CA412603155 rs1211281591	11	P>L	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
rs1481997420 CA412603174	14	K>N		No	ClinGen TOPMed gnomAD
CA412603176 rs1178880511	15	Q>K		No	ClinGen gnomAD
CA412603185 rs1203734629	16	I>V		No	ClinGen TOPMed
CA327701962 rs894111987	18	R>S		No	ClinGen Ensembl
TCGA novel	38	D>Y	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	40	A>T	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA412604054 rs1389849750	40	A>V		No	ClinGen gnomAD
TCGA novel	47	M>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	48	F>S	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs757407648 CA10372233	50	R>L		No	ClinGen ExAC gnomAD
CA412604178 rs1286849807	59	N>S		No	ClinGen TOPMed
TCGA novel	61	M>I	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	62	R>T	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA412604222 rs1569221449	65	N>S		No	ClinGen Ensembl
CA327704133 rs112864206	66	L>I		No	ClinGen gnomAD
CA412604226 rs112864206	66	L>V		No	ClinGen gnomAD
rs373610926 CA10372237	68	P>L		No	ClinGen ESP ExAC TOPMed gnomAD
CA412604238 rs1356193750	68	P>S		No	ClinGen Ensembl
rs781685582 CA412604281	74	R>H		No	ClinGen ExAC gnomAD
CA10372239 rs781685582	74	R>L		No	ClinGen ExAC gnomAD
rs1248307088 CA412604296	77	V>M		No	ClinGen TOPMed
TCGA novel	78	G>*	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA412604301 rs1320984152	78	G>R		No	ClinGen gnomAD
CA412604336 rs1219289154	83	W>R		No	ClinGen gnomAD
CA412604439 rs1283683483	84	Y>H		No	ClinGen gnomAD
rs1251479970 CA412604447	85	M>V		No	ClinGen TOPMed
rs752176446 CA10372260	89	L>F		No	ClinGen ExAC
CA327704406 rs865809787	96	N>Y		No	ClinGen Ensembl
CA412604553 rs1438801923	99	P>S		No	ClinGen TOPMed
CA10372262 rs781697878	100	E>K		No	ClinGen ExAC
CA412604568 rs1242976735	101	D>G		No	ClinGen gnomAD
rs753059452 CA10372263	101	D>N		No	ClinGen ExAC gnomAD
CA412604603 rs1186311518	106	D>G		No	ClinGen gnomAD
CA327704768 rs377312196	107	N>K		No	ClinGen Ensembl
rs751628881 CA10372277	110	Q>H		No	ClinGen ExAC gnomAD
CA412605141 rs1569223291	113	I>T		No	ClinGen Ensembl
rs768094116 CA10372279	114	K>E		No	ClinGen ExAC TOPMed gnomAD
CA412605253 rs1569223305	129	G>V		No	ClinGen Ensembl
TCGA novel	134	K>N	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA327704772 rs1057438680	143	I>V		No	ClinGen TOPMed gnomAD
CA412605361 rs1362625763	144	S>N		No	ClinGen gnomAD
rs1186559746 CA412605368	145	T>S		No	ClinGen gnomAD
TCGA novel	153	R>Q	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1379878511 CA874157694	155	Y>*		No	ClinGen TOPMed
CA10372283 rs753439893	158	R>C		No	ClinGen ExAC gnomAD
rs867468579 CA327704773	162	R>L		No	ClinGen Ensembl
CA10372285 rs778417767	169	T>A		No	ClinGen ExAC gnomAD
rs1440092591 CA412605552	170	L>V		No	ClinGen gnomAD
CA10372298 rs149603823	175	D>N		No	ClinGen ExAC TOPMed gnomAD
CA327704861 rs1001427966	176	T>A		No	ClinGen Ensembl
rs1251852375 CA412605627	181	P>L		No	ClinGen gnomAD
rs1195105052 CA412605645	184	I>V		No	ClinGen gnomAD
CA412605654 rs1358416195	185	G>E		No	ClinGen TOPMed
rs761179602 CA10372300	186	S>G		No	ClinGen ExAC gnomAD
CA10372302 rs751045824	191	C>G		No	ClinGen 1000Genomes ExAC gnomAD
CA10372305 rs750057089	194	A>V	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
CA10372319 rs776972682	199	D>G		No	ClinGen ExAC TOPMed gnomAD
CA412605746 rs1379964721	199	D>N	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
rs910823377 CA327705857	203	T>P		No	ClinGen Ensembl
rs1228681568 CA412602243	205	K>E		No	ClinGen gnomAD
VAR_042297	219	E>A	a head & neck squamous cell carcinoma sample; somatic mutation [UniProt]	No	UniProt
CA10372321 rs200598034	224	N>S		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
rs746108651 CA10372332	227	A>V		No	ClinGen ExAC TOPMed gnomAD
CA412602421 rs775466691	228	P>L		No	ClinGen ExAC TOPMed gnomAD
CA10372334 rs775466691	228	P>Q		No	ClinGen ExAC TOPMed gnomAD
rs369738728 CA10372336	230	K>R		No	ClinGen ESP ExAC TOPMed gnomAD
rs1209829135 CA412602450	233	Q>E		No	ClinGen gnomAD
rs1209829135 CA412602449	233	Q>K		No	ClinGen gnomAD
rs1164300946 CA412602461	234	V>A		No	ClinGen gnomAD
rs1255155996 CA412602483	238	P>S		No	ClinGen gnomAD
CA412602533 rs1486575043	245	L>I		No	ClinGen gnomAD
CA412602570 rs1447713476	250	K>E		No	ClinGen TOPMed
rs988429576 CA327706473	252	S>L		No	ClinGen TOPMed
CA10372351 rs756972308	255	A>V		No	ClinGen ExAC gnomAD
rs747187153 CA10372353	260	Y>C		No	ClinGen ExAC gnomAD
CA10372352 rs780372283	260	Y>H		No	ClinGen ExAC
rs768849028 CA10372354	262	D>G		No	ClinGen ExAC gnomAD
TCGA novel	264	K>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA10372355 rs781064695	267	Y>H		No	ClinGen ExAC TOPMed gnomAD
CA10372358 rs773597771	274	V>I	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
CA327706474 rs929575020	282	S>Y		No	ClinGen Ensembl
rs1569227341 CA412602855	288	L>V		No	ClinGen Ensembl
TCGA novel	291	G>D	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA412602883 rs1293194420	293	P>S		No	ClinGen gnomAD
COSM1119511 rs868382375 CA327706499	295	R>*	Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated NCI-TCGA TOPMed gnomAD
COSM171971 rs1192081613 CA412602924	299	R>C	large_intestine Variant assessed as Somatic; 6.267e-05 impact. [Cosmic, NCI-TCGA]	No	ClinGen cosmic curated NCI-TCGA gnomAD
TCGA novel	308	A>D	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	312	S>N	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1460435676 CA412603061	319	A>D		No	ClinGen gnomAD
CA412603060 rs1401728248	319	A>T		No	ClinGen gnomAD
CA327706737 rs990531239	325	G>V		No	ClinGen TOPMed gnomAD
CA10372374 rs375056431	330	I>L		No	ClinGen ESP ExAC gnomAD
rs1188703986 CA412603373	332	R>C		No	ClinGen gnomAD
CA327706738 rs368054026	332	R>H		No	ClinGen ESP TOPMed
VAR_070083	334	Y>S		No	UniProt
rs5986591 CA327706739	336	R>K		No	ClinGen Ensembl
rs1424911471 CA412603429	337	Y>H		No	ClinGen gnomAD
TCGA novel	346	S>T	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs774523978 CA10372378	349	G>R		No	ClinGen ExAC TOPMed gnomAD
rs1405510156 CA412603534	352	T>S		No	ClinGen gnomAD
CA412603554 rs1602128608	355	V>D		No	ClinGen Ensembl
CA412603551 rs1602128602	355	V>I		No	ClinGen Ensembl
CA412603567 rs1247748997	357	Y>S		No	ClinGen Ensembl
TCGA novel	365	S>P	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA412603726 rs1356075616	378	R>C	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed gnomAD
TCGA novel	381	K>N	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA10372404 rs775948695	385	E>K	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
TCGA novel	387	D>N	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1371381526 CA412603848	395	E>K		No	ClinGen TOPMed gnomAD
CA10372405 rs761831322	396	P>L		No	ClinGen ExAC
rs765044068 CA10372406	398	D>G		No	ClinGen ExAC TOPMed gnomAD
rs371788046 CA10372407	401	K>R		No	ClinGen ESP ExAC TOPMed
TCGA novel	405	K>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA

1 associated diseases with Q15120

[MIM: 300905]: Charcot-Marie-Tooth disease, X-linked dominant, 6 (CMTX6)

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology

Without disease ID

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology

13 regional properties for Q15120

Type	Name	Position	InterPro Accession
repeat	HAT (Half-A-TPR) repeat	222 - 254	IPR003107-1
repeat	HAT (Half-A-TPR) repeat	256 - 288	IPR003107-2
repeat	HAT (Half-A-TPR) repeat	290 - 322	IPR003107-3
repeat	HAT (Half-A-TPR) repeat	324 - 355	IPR003107-4
repeat	HAT (Half-A-TPR) repeat	357 - 388	IPR003107-5
repeat	HAT (Half-A-TPR) repeat	390 - 425	IPR003107-6
repeat	HAT (Half-A-TPR) repeat	427 - 461	IPR003107-7
repeat	HAT (Half-A-TPR) repeat	505 - 539	IPR003107-8
repeat	HAT (Half-A-TPR) repeat	549 - 585	IPR003107-9
repeat	HAT (Half-A-TPR) repeat	587 - 618	IPR003107-10
repeat	HAT (Half-A-TPR) repeat	620 - 652	IPR003107-11
repeat	HAT (Half-A-TPR) repeat	654 - 688	IPR003107-12
repeat	HAT (Half-A-TPR) repeat	690 - 721	IPR003107-13

Functions

		Description
EC Number	2.7.11.2	Protein-serine/threonine kinases
Subcellular Localization	Mitochondrion matrix
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

3 GO annotations of cellular component

Name	Definition
mitochondrial matrix	The gel-like material, with considerable fine structure, that lies in the matrix space, or lumen, of a mitochondrion. It contains the enzymes of the tricarboxylic acid cycle and, in some organisms, the enzymes concerned with fatty acid oxidation.
mitochondrion	A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration.
nucleolus	A small, dense body one or more of which are present in the nucleus of eukaryotic cells. It is rich in RNA and protein, is not bounded by a limiting membrane, and is not seen during mitosis. Its prime function is the transcription of the nucleolar DNA into 45S ribosomal-precursor RNA, the processing of this RNA into 5.8S, 18S, and 28S components of ribosomal RNA, and the association of these components with 5S RNA and proteins synthesized outside the nucleolus. This association results in the formation of ribonucleoprotein precursors; these pass into the cytoplasm and mature into the 40S and 60S subunits of the ribosome.

4 GO annotations of molecular function

Name	Definition
ATP binding	Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
protein kinase activity	Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.
protein serine/threonine kinase activity	Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.
pyruvate dehydrogenase (acetyl-transferring) kinase activity	Catalysis of the reaction: ATP + pyruvate dehydrogenase (acetyl-transferring) = ADP + pyruvate dehydrogenase (acetyl-transferring) phosphate.

10 GO annotations of biological process

Name	Definition
cellular response to fatty acid	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fatty acid stimulus.
cellular response to glucose stimulus	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucose stimulus.
glucose metabolic process	The chemical reactions and pathways involving glucose, the aldohexose gluco-hexose. D-glucose is dextrorotatory and is sometimes known as dextrose; it is an important source of energy for living organisms and is found free as well as combined in homo- and hetero-oligosaccharides and polysaccharides.
hypoxia-inducible factor-1alpha signaling pathway	The series of molecular signals mediated by hypoxia-inducible factor (HIF1) in response to lowered oxygen levels (hypoxia). Under hypoxic conditions, the oxygen-sensitive alpha-subunit of hypoxia-inducible factor (HIF)-1 dimerizes with a HIF1-beta subunit (also called ARNT or aryl-hydrocarbon-receptor nuclear translocator), translocates to the nucleus and activates transcription of genes whose products participate in responding to hypoxia.
peptidyl-serine phosphorylation	The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine.
peroxisome proliferator activated receptor signaling pathway	The series of molecular signals initiated by binding of a ligand to any of the peroxisome proliferator activated receptors (alpha, beta or gamma) in the nuclear membrane, and ending with the initiation or termination of the transcription of target genes.
protein phosphorylation	The process of introducing a phosphate group on to a protein.
regulation of acetyl-CoA biosynthetic process from pyruvate	Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of acetyl-CoA from pyruvate.
regulation of glucose metabolic process	Any process that modulates the rate, frequency or extent of glucose metabolism. Glucose metabolic processes are the chemical reactions and pathways involving glucose, the aldohexose gluco-hexose.
regulation of reactive oxygen species metabolic process	Any process that modulates the frequency, rate or extent of reactive oxygen species metabolic process.

3 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
Q15118	PDK1	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (Human)	PR
O55028	Bckdk	[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial	Mus musculus (Mouse)	PR
Q00972	Bckdk	[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial	Rattus norvegicus (Rat)	PR

10	20	30	40	50	60
MRLFRWLLKQ	PVPKQIERYS	RFSPSPLSIK	QFLDFGRDNA	CEKTSYMFLR	KELPVRLANT
70	80	90	100	110	120
MREVNLLPDN	LLNRPSVGLV	QSWYMQSFLE	LLEYENKSPE	DPQVLDNFLQ	VLIKVRNRHN
130	140	150	160	170	180
DVVPTMAQGV	IEYKEKFGFD	PFISTNIQYF	LDRFYTNRIS	FRMLINQHTL	LFGGDTNPVH
190	200	210	220	230	240
PKHIGSIDPT	CNVADVVKDA	YETAKMLCEQ	YYLVAPELEV	EEFNAKAPDK	PIQVVYVPSH
250	260	270	280	290	300
LFHMLFELFK	NSMRATVELY	EDRKEGYPAV	KTLVTLGKED	LSIKISDLGG	GVPLRKIDRL
310	320	330	340	350	360
FNYMYSTAPR	PSLEPTRAAP	LAGFGYGLPI	SRLYARYFQG	DLKLYSMEGV	GTDAVIYLKA
370	380	390	400
LSSESFERLP	VFNKSAWRHY	KTTPEADDWS	NPSSEPRDAS	KYKAKQ